Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Abenhardt · SciRah

Researcher profile · Semantic Scholar

W. Abenhardt

Share profile

W. Abenhardt — researcher profile on SciRah

h-index: 14
Works: 69
Citations: 821

Most-cited papers

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
N. Moosmann, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +16 more
2011Journal of Clinical Oncology114 citations
Semantic Scholar
Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
C. Schweighofer, M. Ritgen, B. Eichhorst, R. Busch +4 more
2009British Journal of Haematology108 citations
Semantic Scholar
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
A. Hartkopf, J. Huober, B. Volz, N. Nabieva +29 more
2018Breast63 citations Open access
Semantic Scholar
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
M. Hoechstetter, Raymonde Busch, B. Eichhorst, A. Bühler +22 more
2017Leukemia56 citations
Semantic Scholar
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
M. Lux, N. Nabieva, A. Hartkopf, J. Huober +27 more
2018Cancers48 citations Open access
Semantic Scholar
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
I. Witzel, V. Müller, W. Abenhardt, M. Kaufmann +3 more
2014BMC Cancer47 citations Open access
Semantic Scholar
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
M. Hoechstetter, R. Busch, B. Eichhorst, A. Bühler +25 more
2020Leukemia40 citations
Semantic Scholar
Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma
O. Schnell, J. Thorsteinsdottir, D. F. Fleischmann, M. Lenski +6 more
2016Journal of Neuro-Oncology35 citations
Semantic Scholar
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H. Stemmler, D. Digioia, W. Freier, H. Tessen +10 more
2011British Journal of Cancer34 citations Open access
Semantic Scholar
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
S. Stintzing, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +15 more
2011British Journal of Cancer30 citations Open access
Semantic Scholar
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer
H. Stemmler, N. Harbeck, Isolde Gröll de Rivera, U. Vehling-Kaiser +7 more
2011Oncology24 citations Open access
Semantic Scholar
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms
W. Knauf, W. Abenhardt, S. Dörfel, D. Meyer +4 more
2014Hematological Oncology21 citations Open access
Semantic Scholar
Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms
W. Knauf, W. Abenhardt, J. Mohm, J. Rauh +4 more
2019European Journal of Haematology16 citations Open access
Semantic Scholar
High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer
J. Stemmler, W. Mair, M. Stauch, J. Papke +11 more
2005Oncology16 citations Open access
Semantic Scholar
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression
V. Nüssler, F. Gieseler, H. Zwierzina, E. Gullis +8 more
1997Annals of Hematology13 citations
Semantic Scholar
Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
R. Chekerov, P. Harter, S. Fuxius, L. Hanker +14 more
2017Gynecologic Oncology Research and Practice12 citations Open access
Semantic Scholar
Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).
M. Bergmann, B. Eichhorst, R. Busch, H. Doehner +3 more
200712 citations
Semantic Scholar
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial
O. Al-Sawaf, K. Fischer, C. Herling, M. Ritgen +11 more
2017European Journal of Haematology11 citations
Semantic Scholar
Treatment of Non-Transplant Patients with Multiple Myeloma: Routine Treatment by Office-Based Haematologists in Germany - Data from the Prospective Tumour Registry Lymphatic Neoplasms (TLN)
W. Knauf, W. Abenhardt, A. Aldaoud, A. Nusch +5 more
2014Oncology Research and Treatment11 citations Open access
Semantic Scholar
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms
W. Knauf, W. Abenhardt, M. Koenigsmann, C. Maintz +7 more
2021Hematological Oncology10 citations Open access
Semantic Scholar
Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).
K. Fischer, C. Schweighofer, M. Ritgen, S. Boettcher +7 more
200710 citations
Semantic Scholar
Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors
P. Bojko, G. Schimmel, D. Bosse, W. Abenhardt
2012Oncology Research and Treatment9 citations
Semantic Scholar
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer
H. Stemmler, N. Harbeck, Isolde Gröll de Rivera, U. Vehling-Kaiser +7 more
2011Oncology9 citations Open access
Semantic Scholar
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
A. Welt, M. Wiesweg, S. Theurer, W. Abenhardt +10 more
2020Cancer Medicine8 citations Open access
Semantic Scholar
Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry
J. Huober, P. Fasching, F. Taran, B. Volz +27 more
20187 citations
Semantic Scholar
Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry
F. Taran, P. Fasching, B. Volz, J. Huober +27 more
20187 citations
Semantic Scholar
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
J. Thaler, R. Greil, Johannes Gaenzer, W. Eisterer +318 more
2015Annals of Oncology7 citations Open access
Semantic Scholar
Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)
A. Schneeweiss, M. Lux, A. Hartkopf, B. Volz +27 more
2019Poster Session Abstracts5 citations
Semantic Scholar
A Multicenter Prospective Randomized Trial with Assessment of Quality of Life in Patients with Metastatic Colorectal Carcinoma Comparing Interferon α-2b and Folinic Acid as Modulators of 5-Fluorouracil
E. Kreuser, T. Küchler, T. Zwingers, M. Matthias +20 more
19945 citations
Semantic Scholar
Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms
W. Knauf, W. Abenhardt, H. Slawik, Ute Bückner +7 more
2020Hematological Oncology4 citations Open access
Semantic Scholar
Mutations in the JAK2 and MPL Genes and their Correlation to Clinical Parameters in Patients with Chronic Myeloproliferative Disease
P. Bojko, W. Abenhardt, S. Schnittger, T. Haferlach
2009Oncology Research and Treatment4 citations
Semantic Scholar
[Early changes in thyroid hormones following radioiodine therapy of hyperthyroidism with reference to etiology and accompanying medication].
T. Kreisig, W. Abenhardt, K. Mann, C. Kirsch +1 more
1989Klinische Wochenschrift4 citations
Semantic Scholar
Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
M. Hoechstetter, W. Knauf, S. Dambacher, N. Hucke +5 more
2022Clinical Lymphoma, Myeloma & Leukemia3 citations Open access
Semantic Scholar
Insulin and Diazoxide for Treatment of Cancer
M. Fink, W. Abenhardt, B. Ostermayr, M. Berger
19913 citations
Semantic Scholar
Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry
W. Knauf, W. Abenhardt, E. Engel, R. Grugel +2 more
20132 citations
Semantic Scholar
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.
D. Modest, R. Laubender, L. V. von Weikersthal, U. Vehling-Kaiser +16 more
20122 citations
Semantic Scholar
Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres
W. Knauf, W. Abenhardt, A. Nusch, R. Grugel +1 more
20122 citations
Semantic Scholar
9146 Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response
C. Schumann, D. Heigener, I. Dittrich, W. Abenhardt +6 more
20092 citations
Semantic Scholar
Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC)
W. Freier, H. Stemmler, H. Tessen, Gerald Gitsch +6 more
20082 citations
Semantic Scholar
FDG-PET: An Important Tool in the Diagnosis of Lung Cancer
W. Abenhardt
2007Oncology Research and Treatment2 citations Open access
Semantic Scholar
Non-Interventional Study Hexafil: G-CSF Use in Accordance to Guidelines?
H. Tesch, W. Abenhardt, L. Dietze, D. T. Chang +1 more
20121 citations
Semantic Scholar
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
V. Heinemann, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +15 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
Germ cell tumor (GCT): Staging and therapy control with 18FDG-PET. First results of German multicenter trial
M. D. de Wit, C. Bokemeyer, D. Hartmann, W. Abenhardt +6 more
19971 citations
Semantic Scholar
OnkoCampus
L. Böning, W. Abenhardt, M. Hallek
2023Kompass Onkologie0 citations
Semantic Scholar
Author response for "Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms"
W. Knauf, W. Abenhardt, Hans Rainer Slawik, Ute Bückner +7 more
20200 citations
Semantic Scholar
PS1163 PATIENT-BASED PROSPECTIVE REAL WORLD DATA ANALYSIS SHOWS THAT THE DURATION OF TREATMENT INTERRUPTIONS WITH SUBSEQUENT RESUMPTION OF IDELALISIB THERAPY CAN VARY FROM DAYS TO MONTHS
Manuela Hoechstetter, W. Knauf, Philipp Eissmann, N. Hucke +3 more
2019HemaSphere0 citations Open access
Semantic Scholar
Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)
M. Lux, A. Hartkopf, J. Huober, B. Volz +27 more
2019Poster Session Abstracts0 citations
Semantic Scholar
Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease
E. Grischke, A. Nusch, N. Marschner, W. Abenhardt +10 more
20160 citations
Semantic Scholar
Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC).
H. Stemmler, N. Harbeck, I. Groell der Rivera, U. Vehling-Kaiser +6 more
2016Journal of Clinical Oncology0 citations
Semantic Scholar
PO-0798: Bevacizumab treatment in recurrent malignant glioma patients – mono-institutional experience in 125 patients
M. Niyazi, J. Thorsteinsdottir, D. Fleischmann, W. Abenhardt +3 more
20150 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

U. Vehling-Kaiser×11
Invite
U. Vehling-Kaiser — researcher profile on SciRah
W. Knauf×10
Invite
W. Knauf — researcher profile on SciRah
N. Marschner×10
Invite
N. Marschner — researcher profile on SciRah
V. Heinemann×9
Invite
V. Heinemann — researcher profile on SciRah

×8

Invite

H. Tesch — researcher profile on SciRah

Invite

F. Overkamp — researcher profile on SciRah

P. Wimberger×7

Invite

P. Wimberger — researcher profile on SciRah

C. Kurbacher×7

Invite

C. Kurbacher — researcher profile on SciRah

B. Eichhorst×6

Invite

B. Eichhorst — researcher profile on SciRah

Invite

B. Volz — researcher profile on SciRah

Invite

F. Taran — researcher profile on SciRah

E. Belleville×6

Invite

E. Belleville — researcher profile on SciRah